Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Tandem Diabetes Care's enterprise value is $1,914 Mil.
Tandem Diabetes Care's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-37 Mil. Therefore, Tandem Diabetes Care's EV-to-EBITDA for today is -52.19.
The historical rank and industry rank for Tandem Diabetes Care's EV-to-EBITDA or its related term are showing as below:
TNDM'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -4498.52 Med: -11.56 Max: 669.55
Current: -52.19
During the past 13 years, the highest EV-to-EBITDA of Tandem Diabetes Care was 669.55. The lowest was -4498.52. And the median was -11.56.
TNDM's EV-to-EBITDA is ranked worse than 100% of 515
companies
in the Medical Devices & Instruments industry
Industry Median: 15.16
vs TNDM: -52.19
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Tandem Diabetes Care (NAS:TNDM) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Tandem Diabetes Care's PE Ratio (TTM) for today is calculated as:
Tandem Diabetes Care's share price for today is $23.44.
Tandem Diabetes Care's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.930.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Tandem Diabetes Care's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Tandem Diabetes Care's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tandem Diabetes Care EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Tandem Diabetes Care's EV-to-EBITDA falls into.
Tandem Diabetes Care's current Enterprise Value is $1,914 Mil.
Tandem Diabetes Care's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-37 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tandem Diabetes Care (TNDM) has a EV-to-EBITDA of -52.19 as of Aug. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Tandem Diabetes Care. According to the industry distribution chart, Tandem Diabetes Care ranks #999999 out of 515 companies in the Medical Devices & Instruments industry.
Is Tandem Diabetes Care's EV-to-EBITDA too high?
Tandem Diabetes Care's current EV-to-EBITDA is -52.19. Based on the distribution chart, Tandem Diabetes Care ranks #999999 out of 515 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Tandem Diabetes Care has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tandem Diabetes Care's EV-to-EBITDA compare to AVNS and IRMD?
According to the Medical Devices & Instruments industry distribution chart, Tandem Diabetes Care ranks #999999 out of 515 companies for EV-to-EBITDA. This places Tandem Diabetes Care in the lower half of its industry. The industry median EV-to-EBITDA is 15.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 15.16, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Tandem Diabetes Care. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 15.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tandem Diabetes Care's current EV-to-EBITDA is -52.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tandem Diabetes Care stock overvalued right now?
Based on GuruFocus' analysis, Tandem Diabetes Care (TNDM) is currently considered Fairly Valued. The stock's GF Value™ is $24.01, compared to a current price of $23.44 — trading 2.4% below its estimated fair value. The current EV-to-EBITDA is -52.19. Tandem Diabetes Care's overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Tandem Diabetes Care (TNDM), the current EV-to-EBITDA is -52.19 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tandem Diabetes Care (TNDM) Overvalued in 2026?
Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued.
The current stock price of $23.44 is trading 2.4% below its estimated GF Value™ of $24.01.
GuruFocus considers Tandem Diabetes Care to be Fairly Valued.
Key valuation signals for TNDM:
EV-to-EBITDA: -52.19
GF Value™: $24.01 vs. price of $23.44 (2.4% below fair value)
No single metric tells the full story. See the TNDM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
71GF Score
Get the complete analysis for TNDM
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TNDM has been successfully added to your 
